LearnGlossaryMarketStocksSuperinvestorsSign in

AGIO

Agios Pharmaceuticals, Inc.

Healthcare · $2.0B market cap

Verdict

We can't put a fair value on AGIO right now. Its earnings are too small compared with its share price for an earnings-based value to mean anything.

Business quality

0 of 5 clear the 10% bar. What are the Big Five?

Earnings per share growth—?
Equity per share growth8.2% a year✗
Sales growth5.0% a year✗
Free cash flow growth—?
Return on invested capital-35.8%✗

Follow AGIO

Track it on your watchlist and see the full analysis. Free.

Create a free account

About Agios Pharmaceuticals, Inc.

Agios Pharmaceuticals, Inc. is a biopharmaceutical firm dedicated to the research and advancement of new treatments, specifically targeting cellular metabolism and related biological fields. The company's offerings include PYRUKYND (mitapivat), a medication designed to activate both wild-type and various mutated pyruvate kinase (PK) enzymes, used in the management of hemolytic anemias. Additionally, Agios is…

Biotechnology

Fair value and Payback Price are estimates from the company's reported financials, not investment advice. Prices as of the close of Oct 3, 2026. How the Payback Price works